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In a recent publication in Bioscience Reports “Contaminants in commercial preparations of
‘purified’ small leucine-rich proteoglycans may distort mechanistic studies”, Brown et al.
identified by mass spectrometry and immunoblotting that certain commercial preparations
of the small leucine-rich proteoglycans (SLRPs) decorin and biglycan, in fact, contained a
mix of several proteoglycans that also included fibromodulin and aggrecan. The prepara-
tions were thus not suitable to study specific activities of decorin or biglycan. Decorin and
biglycan are widely studied SLRPs that are considered to have highly multi-functional ef-
fects on cells. Decorin is of interest as a transforming growth factor-β antagonist and is also
finding use in tissue engineering materials. This Commentary discusses Brown et al.’s find-
ings and general issues raised for researchers who work with commercially sourced purified
proteoglycans.
The SLRPs
Brown et al. set out to study possible functional roles of the secreted, small leucine-rich proteoglycans
(SLRPs) decorin and biglycan in supporting neurite outgrowth [1]. Proteoglycans are ubiquitous com-
ponents of extracellular matrix (ECM) that are characterized by covalent substitution of one or more,
typically O-linked glycosaminoglycan (GAG) chains on the core protein. Of the secreted proteoglycans
of mammals, SLRPs form the largest gene family with the smallest core proteins (approximately 32–45
kDa) that are composed principally of a series of tandem leucine-rich repeats. Decorin and biglycan are
closely-related SLRPs: their core proteins have 56% sequence identity in humans and are substituted with
one or two chondroitin sulphate/dermatan sulphate-type GAG chains respectively (Table 1). Notwith-
standing their small size, a wide array of functional properties have been attributed to decorin and bigly-
can, including roles in fibrotic diseases, infection and immunity, angiogenesis and tumour microenvi-
ronment. These properties relate to ECM-incorporated decorin and biglycan and also to activities of the
proteins in soluble form. Correspondingly, an extensive set of interaction partners has been identified for
each [2,3]. There is also interest in decorin as a tissue engineering material [4].
The context
Both decorin and biglycan are expressed in intervertebral discs, which, in healthy individuals, are inner-
vated only in the outer region. When discs degenerate, as occurs in ageing or after trauma, alterations in
the disc ECM provide conditions that can allow for nerve ingrowth into central areas [5]. Although the
most prominent phenotype of decorin-null mice is skin fragility [6] and, for biglycan-null mice, effects on
growth of the long bones [7], both proteoglycans are known to affect motility and neurite outgrowth of
neuronal cells and are up-regulated in the brain after injury [8,9]. Decorin promotes neurogenesis down-
stream of Wnt7a [10], and is of translational interest for reduction of scarring after spinal cord injury
[11].
c© 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Table 1 Some characteristics of the major proteoglycans identiﬁed by Brown et al. [1] in commercial preparations of
decorin or biglycan
Characteristic PG
Biglycan Decorin Fibromodulin Aggrecan
SLRP (Yes/No) Yes Yes Yes No
Mol. weight of core protein* (kDa) 41.7 38.8 43.2 250.4
Types and number of GAG
chains
CS/DS (1 chain) CS/DS (2 chains) KS (4 chains) CS/KS (multiple chains)
*Predicted molecular weights are based on the human proteins; CS, chondroitin sulphate; DS, dermatan sulphate; KS, keratan sulphate.
Given the presence of decorin and biglycan in intervertebral discs, the authors’ goal was to examine the activity of
these SLRPs as substrata for neurite outgrowth by sensory neurons from dorsal root ganglia (DRG) explants. Their
assay involved coating dishes with stripes of collagen I (an adhesive protein for neurons in vitro), interspersed with
stripes of decorin or biglycan. The effects of decorin or biglycan, whether to support or repel neurites extending
in from the collagen-coated strips, were then assessed microscopically. The DRG were from chick embryos and the
proteoglycans were preparations from bovine articular cartilage, purchased from Sigma [1].
The problem
As expected, the decorin and biglycan preparations inhibited neurite outgrowth, as measured by a
concentration-dependent inhibition of entry of neurites on to the respective strips. However, warning bells
were rung when treatment of the proteoglycans with chondroitinase AC, which cleaves chondroitin sulphate chains,
failed to block inhibition. The authors entered into a series of control experiments. The identification of keratan
sulphate in the preparations by immunoblotting with a highly specific antibody raised further concerns, because
neither decorin nor biglycan is known to be substituted by keratan sulphate chains (Table 1). The authors, therefore,
subjected the major protein bands detected after enzymatic removal of chondroitin sulphate, dermatan sulphate and
keratan sulphate side chains to mass spectrometry analysis. Startlingly, biglycan was the most prominent protein in
the decorin preparation: indeed the peptides from decorin did not meet the threshold for statistical significance.
Consistent with the detection of keratan sulphate, fibromodulin and aggrecan were identified in both the biglycan
and decorin preparations ( [1], Supplementary material) (Table 1). Finally, the authors immunoblotted the biglycan
preparation for all the identified core proteins, in comparison with an independent preparation of aggrecan from
post-mortem human intervertebral disc. Indeed, decorin, fibromodulin, aggrecan and high molecular weight
keratan sulphate species were detected in the commercial biglycan preparation along with biglycan, whereas lumican
(included in the tests as a protein not detected by mass spectrometry) was not detected. In the decorin preparation,
biglycan and aggrecan were also detected by immunoblot. Thus, the preparations were found to be unsuitable for
the study of specific properties of decorin or biglycan. The authors discuss their results with regard to lost time and
resources and the implications for previous research publications frommany laboratories in which these preparations
have been used [1].
Any roses anywhere?
Researchers who work with these preparations will benefit from the full list of protein components identified by
mass spectrometry. Could the co-isolated proteoglycans represent components of biologically relevant, multi-protein
complexes from cartilage ECM? Although SLRPs are known as collagen-binding proteoglycans, and decorin is not
registered as a binding partner of other SLRPs [3], native SLRPs frombovine nasal cartilage have beendemonstrated to
bind hyaluronate-Sepharose, suggesting a possible mechanism for indirect association with each other and aggrecan
[12]. Furthermore, biochemical purification of proteoglycans from articular cartilage is typically a complex process,
involving guanidinium hydrochloride extraction, followed bymultiple fractionation steps including density-gradient
centrifugation, then size-exclusion chromatography and/or ion-exchange chromatography. Even in such multi-step
schemes, co-purification of SLRPs with each other or with aggrecan has been reported, for example, as in human
articular cartilage [13].
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Further considerations
The present study gives warning to researchers using, or considering to use, commercial decorin and biglycan prepa-
rations from animal (usually bovine) tissues. Commercial sources for recombinantly expressed decorin and biglycan
can provide alternatives. A recombinant preparation was used, for example, to study transforming growth factor-β
antagonism by decorin in a spinal cord injury model [11]. Most suppliers express the proteins in tagged form for
tag-affinity purification. The quality control for purity is usually SDS/PAGE and silver staining. Given that, in most
cases, the SLRP is expressed in mammalian cells, it is not implausible that small amounts of co-purifying ECM pro-
teoglycans, collagens or growth factors might be present. In addition, proteoglycans expressed in mammalian cells
can show variability of GAG substitution, GAG length or sulphation, depending on the cell line and also within the
same preparation [14,15]. Overall, mass spectrometry analysis remains an advisable control. Another solution could
be to work with proteins expressed in insect cells because many proteoglycans of jawed vertebrates are not encoded in
invertebrates [16]. Again, some commercial sources provide insect cell-expressed decorin. However, the addition of
relevant GAG chains and/or GAG sulphation status could be a concern in these more evolutionarily remote systems.
Chondroitin sulphate modifications are known to take place in insects ( [17] and references therein), but whether
epimerization to dermatan sulphate is supported is less clear. Dermatan sulphate epimerase orthologues are predicted
throughout deuterostomes, yet are not identifiable in insects or other arthropods (human NP 001074445 used as a
BLASTP query). Sulphation of chondroitin sulphate chains upon SLRP expression in insect cells appears likely, as pro-
teoglycan biosynthetic enzymes including sulphotransferases related to mammalian chondroitin 6-sulphotransferase
or chondroitin 4-sulphotransferase are present in insects such as Drosophila [18]. Moving to a distinct expression
system may also bring new confounding issues: High Five (BTI-TN-5B1-4) Trichoplusia ni insect cells, popular for
baculovirus expression because of the high amounts of protein produced, secrete an endoglycosidase capable of re-
moving chondroitin sulphate, at least from aggrecan [19].
The overallpicture is that additional experimentalmodes, such as side-by-side testing ofwild-type and decorin-null
cells, gene editing, transcriptional silencing or viral expression of wild-type ormutants,must come to the fore to prove
roles of decorin or biglycan in functional processes of interest. The reminder to ‘know your materials’ is timely in
view of the current drive from researchers, institutions, funding bodies and publishers to enhance the transparency
of research reporting.
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